Job Title: Technician 1 - Plant Metabolism Horticulture
Technician 1 - Plant Metabolism Horticulture
For 70 years, Charles River employees have worked together to assist in the discovery, development and safe manufacture of new drug therapies. When you join our family, you will have a significant impact on the health and well-being of people across the globe. Whether your background is in life sciences, finance, IT, sales or another area, your skills will play an important role in the work we perform. In return, we’ll help you build a career that you can feel passionate about.
At our world class facility in Elphinstone, Tranent (close to Edinburgh), the Plant Metabolism group currently has an exciting career opportunity for a Technician 1.
The Plant Metabolism group provides research services to the agrochemical industry by investigating the metabolism of agrochemicals in crop plants. These studies are conducted with radiolabelled molecules which are applied to a wide variety of temperate and semi-temperate crops grown either outdoors or in glasshouses. The Technician 1 would take a key role in operating our plant metabolism facilities.
- Horticultural tasks include growing and monitoring plants, general crop maintenance, implementing fertiliser and pest prevention regimes, and assisting with horticultural aspects of the scientific research.
- Ensuring smooth running and maintenance of our research grade glasshouses and outdoor trial facilities.
Applicants should have:
- At least 5 Standard Grades (including Maths, English and a science subject) or equivalent.
- A keen interest in science.
- Good communication skills, the ability to pay close attention to detail and a positive and constructive approach to working in a busy scientific environment are essential.
Starting salary for this position is £18,732.
About Safety Assessment
Charles River is committed to helping our partners expedite their preclinical drug development with exceptional safety assessment services, state-of-the-art facilities and expert regulatory guidance. From individual specialty toxicology and IND enabling studies to tailored packages and total laboratory support, our deeply experienced team can design and execute programs that anticipate challenges and avoid roadblocks for a smooth, efficient journey to market. Each year approximately 120 investigational new drug (IND) programs are conducted in our Safety Assessment facilities. The same approaches are used for other product sectors including the development of agrochemical and veterinary medicine products.
About Charles River
Charles River is an early-stage contract research organization (CRO). We have built upon our foundation of laboratory animal medicine and science to develop a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP, to support clients from target identification through preclinical development. Charles River also provides a suite of products and services to support our clients’ clinical laboratory testing needs and manufacturing activities. Utilizing this broad portfolio of products and services enables our clients to create a more flexible drug development model, which reduces their costs, enhances their productivity and effectiveness to increase speed to market.
With over 14,000 employees within 80 facilities in 20 countries around the globe, we are strategically positioned to coordinate worldwide resources and apply multidisciplinary perspectives in resolving our client’s unique challenges. Our client base includes global pharmaceutical companies, biotechnology companies, government agencies and hospitals and academic institutions around the world. And in 2018, revenue increased by 22% to $2.27 billion from $1.86 billion in 2017.
At Charles River, we are passionate about our role in improving the quality of people’s lives. Our mission, our excellent science and our strong sense of purpose guide us in all that we do, and we approach each day with the knowledge that our work helps to improve the health and well-being of many across the globe. We have proudly supported the development of ~85% of the drugs approved by the FDA in 2018.